Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. (Q40464370)

20 September 2017

title

Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. (English)

1 reference

Herpes simplex virus type 1

20 September 2017

main subject

1 reference

Jacqueline N Parker

1

1 reference

20 September 2017

Sreelatha Meleth

2

1 reference

20 September 2017

Kenneth B Hughes

3

1 reference

20 September 2017

G Yancey Gillespie

4

1 reference

20 September 2017

Richard J Whitley

5

1 reference

20 September 2017

James M Markert

6

1 reference

20 September 2017

publication date

1 April 2005

1 reference

20 September 2017

1 reference

20 September 2017

volume

12

1 reference

20 September 2017

issue

4

1 reference

20 September 2017

page(s)

359-368

1 reference

Genetically engineered HSV in the treatment of glioma: a review

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

The application of IL-12 to cytokine therapy and gene therapy for tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

IL-12: a key cytokine in immune regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

Antitumor activity of interleukin 12 in preclinical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

Chemokines as regulators of T cell differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

A generalized technique for deletion of specific genes in large genomes: alpha gene 22 of herpes simplex virus 1 is not essential for growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

Genetics of natural resistance to herpesvirus infections in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

Anti-tumor activity of interleukin-2-producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

Human glioma immunobiology in vitro: implications for immunogene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

Enhanced anti-tumor effects of herpes simplex virus thymidine kinase/ganciclovir system by codelivering monocyte chemoattractant protein-1 in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

Effects on brain tumor cell proliferation by an adenovirus vector that bears the interleukin-4 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

7 January 2021

Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

7 January 2021

Differential roles of CC chemokine ligand 2/monocyte chemotactic protein-1 and CCR2 in the development of T1 immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

7 January 2021

Expression of a herpes simplex virus 1 open reading frame antisense to the gamma(1)34.5 gene and transcribed by an RNA 3' coterminal with the unspliced latency-associated transcript.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

7 January 2021

Neuroblastoma grafts are noninvasively removed within mouse neocortex by selective laser activation of intracellular photolytic chromophore

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

7 January 2021

The chemokine receptor CCR2 mediates the binding and internalization of monocyte chemoattractant protein-1 along brain microvessels.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

7 January 2021

Cyclic variations in cell-mediated immunity to skin allografts detected by the technetium-99m microcytotoxicity assay

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700784

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700784

1 reference

Dimensions Publication ID

20 September 2017

1053722647

0 references

1 reference